Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction.

Acute coronary occlusion results in ischemia-mediated death of cardiomyocytes. In the days and weeks following myocardial infarction (MI), left ventricular remodeling occurs that is characterized by persistent cardiomyocyte apoptosis, thinning and fibrosis at the site of infarction, ventricular chamber dilatation, and growth of remaining viable cardiomyocytes. The p38 mitogen-activated protein kinase (MAPK) signaling cascade has been implicated in the remodeling process. In this work, mice with cardiac-specific expression of a dominant negative mutant form of p38 MAPK (DN-p38alpha) were subjected to MI by occlusion of the left coronary artery. Acute ischemia area was determined by transthoracic echocardiography 2 h after MI surgery, and was found to be nearly identical in DN-p38 mice and their wild-type littermates. Seven days after MI, mice were subjected to repeat echocardiography and histological examination of infarct size. DN-p38 mice had markedly reduced infarct size and increased ventricular systolic function 7 days after MI when compared to wild-type littermates. In addition, DN-p38 mice had less cardiomyocyte apoptosis than wild-type mice in the infarct border zone. Recently, it was discovered that Bcl-X(L) deamidation occurs in vivo, and this results in Bcl-X(L) degradation that sensitizes cells to apoptosis by enhancing BAX activity. Bcl-X(L) deamidation was found to occur in the cardiac tissue of wild-type mice after MI, but was reduced in DN-p38 mice. These results establish that p38 MAPK activity is required for pathological remodeling after MI and suggest that p38 MAPK may promote cardiomyocyte apoptosis through Bcl-X(L) deamidation.

[1]  M. Benito,et al.  P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. , 2003, Molecular biology of the cell.

[2]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[3]  N. Robinson,et al.  Molecular clocks. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Anthony J. Muslin,et al.  14‐3‐3 proteins block apoptosis and differentially regulate MAPK cascades , 2000, The EMBO journal.

[5]  G. Lamas,et al.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. , 1988, The New England journal of medicine.

[6]  Attila Kovacs,et al.  The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. , 2003, The Journal of clinical investigation.

[7]  B. Swynghedauw,et al.  Molecular mechanisms of myocardial remodeling. , 1999, Physiological reviews.

[8]  M. Pfeffer,et al.  Influence of Chronic Captopril Therapy on the Infarcted Left Ventricle of the Rat , 1985, Circulation research.

[9]  D. Aswad,et al.  Isoaspartate in peptides and proteins: formation, significance, and analysis. , 2000, Journal of pharmaceutical and biomedical analysis.

[10]  T. Yue,et al.  Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. , 1999, Circulation.

[11]  R. Zhao,et al.  An oncogenic tyrosine kinase inhibits DNA repair and DNA-damage-induced Bcl-xL deamidation in T cell transformation. , 2004, Cancer cell.

[12]  G. Sandusky,et al.  Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart. , 2001, Journal of molecular and cellular cardiology.

[13]  P. Doevendans,et al.  Targeted Inhibition of p38 Mitogen-activated Protein Kinase Antagonizes Cardiac Injury and Cell Death Following Ischemia-Reperfusion in Vivo* , 2004, Journal of Biological Chemistry.

[14]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[15]  Ellen M. Langer,et al.  Bcl-xL Deamidation Is a Critical Switch in the Regulation of the Response to DNA Damage , 2002, Cell.

[16]  Anthony J. Muslin,et al.  Role of 14-3-3-Mediated p38 Mitogen-Activated Protein Kinase Inhibition in Cardiac Myocyte Survival , 2003, Circulation research.

[17]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[18]  Anthony J. Muslin,et al.  RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. , 1999, The Journal of clinical investigation.

[19]  E. Murphy,et al.  Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning , 2001 .

[20]  M. Pfeffer,et al.  Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. , 1987, Circulation.

[21]  J. Blenis,et al.  ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions , 2004, Microbiology and Molecular Biology Reviews.

[22]  R. Patten,et al.  New concepts in post-infarction ventricular remodeling. , 2003, Reviews in cardiovascular medicine.

[23]  D. Geddes,et al.  Critical appraisal of the mouse model of myocardial infarction , 2004, Experimental physiology.